What’s Next for HIV Vaccines: From Design to Efficacy Testing

Satellite Session at IAS 2015

Sunday, 19 July | 5:00pm - 7:00pm | Room 121-122

Refreshments will be served

The rapidly evolving field of HIV prevention research includes several promising strategies to prevent or treat HIV with a vaccine.

Please join us for an interactive session to explore the latest in HIV vaccine design, development and testing!

  • What are the most promising, cross-platform approaches in development for preventive and therapeutic vaccines?
  • Where are we in efforts to build on the success of the RV144 trial?
  • What is the field learning from studies on novel immunogen design, unique vector platforms, mosaic antigen inserts and prime-boost vaccine regimens?
  • What is the role of emerging strategies to administer broadly neutralizing antibodies by passive immunization?
  • How do innovative efficacy trial designs optimize the evaluation of HIV vaccine candidates?

Speakers and Panelists

  • Nina Russell, Bill & Melinda Gates Foundation
  • Mary Marovich, National Institute of Allergy and Infectious Diseases
  • William Schief, The Scripps Research Institute and IAVI
  • Nelson Michael, US Military HIV Research Program
  • Dan Barouch, Beth Israel Deaconess Medical Center
  • Allan deCamp, HIV Vaccine Trials Network
  • Frank Tomaka, Janssen Pharmaceuticals

Organized by the Stakeholders of the Enterprise

Bill & Melinda Gates Foundation HIV Vaccine Trials Network  International AIDS Vaccine Initiative
Institut National de la Santé et de la Recherche Médicale US Military HIV Research Program  National Institute of Allergy and Infectious Diseases

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account